The Exchange has sought clarification from Vaishali Pharma Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
VAISHALI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Vaishali Pharma to clarify why its financial results for the quarter ended 30 September 2025 do not follow the format prescribed by SEBI under Regulation 33 of the Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. The company is yet to respond to the exchange's query. This appears to be a procedural compliance issue rather than a substantive financial concern. Investors should watch for the company's clarification in the coming days.
This is a routine compliance query and unlikely to have a material impact on the stock price. However, repeated or unresolved clarifications could raise governance concerns among investors.